https://orcid.org/0000-0003-4751-4220
References
- NICE. Bipolar disorder: assessment and management. NICE Clinical Guidelines, No. 185 [Internet]. 2020 [cited 2020 Jun]. Available from: https://www.nice.org.uk/guidance/cg185
- Kapur S, Taylor D, Paton C. The Maudsley prescribing guidelines. Chichester (UK): CRC Press; 2009.
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–1026.
- NICE. Epilepsies: diagnosis and management [Internet] [cited 2020 Jun]. Available from: https://www.nice.org.uk/guidance/cg137/chapter/1-Guidance#sodium-valproate
- NICE. Bipolar disorder: assessment and management [Internet] [cited 2020 Jun]. Available from: https://www.nice.org.uk/guidance/cg185/chapter/1-Recommendations#managing-mania-or-hypomania-in-adults-in-secondary-care-2
- GOV.UK. Press release: valproate banned without the pregnancy prevention programme [Internet] [cited 2020 Feb]. Available from: https://www.gov.uk/government/news/valproate-banned-without-the-pregnancy-prevention-programme
- Sanofi. Depakote (valproate) summary of product characteristics [Internet] [cited 2021 Sep]. Available from: https://www.medicines.org.uk/emc/product/6102/smpc#gref
- Wockhardt UK Ltd. Folic acid summary of product characteristics [Internet] [cited 2021 Sep]. Available from: https://www.medicines.org.uk/emc/product/6998#gref
- European Medicines Agency. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data: substances related to valproate. Assessment report [Internet] [cited 2020 Jun]. Available from: https://www.ema.europa.eu/en/documents/referral/valproate-related-substances-article-31-referral-prac-assessment-report_en.pdf
- Toussi M, Shlaen M, Coste F, et al. Effectiveness of risk minimisation measures for valproate: a drug utilisation study in Europe. Pharmacoepidemiol Drug Saf. 2021;30(3):292–303.
- Charlton R, Damase-Michel C, Hurault-Delarue C, et al; EUROmediSAFE consortium. Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiol Drug Saf. 2019;28(11):1519–1528.
- Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348–355.
- Baldwin DS, Amaro HJF. Prescription of valproate-containing medicines in women of childbearing potential who have psychiatric disorders: is it worth the risk? CNS Drugs. 2020;34(2):163–169.
- Macfarlane A, Greenhalgh T. Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach? BMC Pregnancy Childbirth. 2018;18(1):200.
- EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66(3):354–360.
- Harris L, Lowes O, Angus-Leppan H. Treatment decisions in women of childbearing age on valproate. Acta Neurol Scand. 2020;141(4):287–293.
- Jick H, Jick SS, Derby LE, et al. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766–768.